Chagas Disease

5
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
1 program
1
Implantable Cardiac MonitorPhase 41 trial
Active Trials
NCT01539161Terminated12Est. Apr 2015
Novartis
NovartisBASEL, Switzerland
1 program
1
Sacubitril/valsartanPhase 4Small Molecule1 trial
Active Trials
NCT04023227Completed918Est. Mar 2025
M&
Merck & Co.RAHWAY, NJ
1 program
1
PosaconazolePhase 2Small Molecule1 trial
Active Trials
NCT01377480Completed120Est. Jan 2015
Bayer
BayerLEVERKUSEN, Germany
2 programs
2
NifurtimoxPhase 11 trial
NifurtimoxPhase 11 trial
Active Trials
NCT03350295Completed48Est. Dec 2018
NCT02606864Completed36Est. Aug 2016
L
LabcorpNC - Burlington
1 program
Congenital Transmission of Lineages I and II of Trypanosoma CruziN/A1 trial
Active Trials
NCT01787968Completed28,348Est. Dec 2013
Abbott
AbbottABBOTT PARK, IL
1 program
Testing Donor Specimens with ESA ChagasN/A1 trial
Active Trials
NCT01662362Completed63Est. Dec 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisSacubitril/valsartan
Rhythm PharmaceuticalsImplantable Cardiac Monitor
Merck & Co.Posaconazole
BayerNifurtimox
BayerNifurtimox
AbbottTesting Donor Specimens with ESA Chagas
LabcorpCongenital Transmission of Lineages I and II of Trypanosoma Cruzi

Clinical Trials (7)

Total enrollment: 29,545 patients across 7 trials

NCT04023227NovartisSacubitril/valsartan

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Start: Dec 2019Est. completion: Mar 2025918 patients
Phase 4Completed
NCT01539161Rhythm PharmaceuticalsImplantable Cardiac Monitor

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

Start: Jul 2013Est. completion: Apr 201512 patients
Phase 4Terminated
NCT01377480Merck & Co.Posaconazole

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

Start: Jul 2011Est. completion: Jan 2015120 patients
Phase 2Completed
NCT03350295BayerNifurtimox

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Start: Jun 2018Est. completion: Dec 201848 patients
Phase 1Completed
NCT02606864BayerNifurtimox

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients

Start: Dec 2015Est. completion: Aug 201636 patients
Phase 1Completed
NCT01662362AbbottTesting Donor Specimens with ESA Chagas

Abbott ESA Chagas Assay Post-Market Study

Start: Jul 2012Est. completion: Dec 201263 patients
N/ACompleted
NCT01787968LabcorpCongenital Transmission of Lineages I and II of Trypanosoma Cruzi

Congenital Transmission of Lineages I and II of Trypanosoma Cruzi

Start: Apr 2011Est. completion: Dec 201328,348 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space